Current Report Filing (8-k)
March 07 2017 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 7, 2017
Aerie Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36152
|
|
20-3109565
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
2030 Main Street, Suite 1500
Irvine, California 92614
(Address of principal executive offices) (Zip code)
Registrants telephone number, including area code:
(949) 526-8700
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On March 7, 2017, Aerie Pharmaceuticals, Inc. (the
Company) issued a press release announcing its financial results for the fourth quarter ended December 31, 2016. A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item
2.02.
The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the
Securities Act), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
99.1 Press Release dated March 7, 2017.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
AERIE PHARMACEUTICALS, INC.
|
|
|
|
Date: March 7, 2017
|
|
By:
|
|
/s/ Richard J. Rubino
|
|
|
|
|
Richard J. Rubino
|
|
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press Release dated March 7, 2017.
|
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2024 to May 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From May 2023 to May 2024